So what: Most of you are probably scratching your head right now wondering what that sentence means. In simple terms, the certification Orexigen received states that Actavis ( AGN ) has taken steps to file an abbreviated new drug application for a generic version of Contrave, Orexigen's and Takeda's weight control management drug approved last year. In short, Actavis is challenging Orexigen's patents, which means Orexigen now needs to go on the defensive and protect its intellectual property rights.